AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05305586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint retained by Bulk-fill flowable
Description: Luxated teeth were splinted with bulk-fill flowable composite
Study NCT05305586 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint retained by Packable Composite
Description: Luxated teeth were splinted with packable composite
Study NCT02719483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swiss DolorClast
Description: Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied.
Study NCT02719483 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional conservative therapy
Description: Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
Study NCT02719483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional conservative therapy
Description: Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
Study NCT02763345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting LIFE electronic Community Case Management
Description: The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
Study NCT02763345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT01905605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphatidylcholine supplementation
Description: phosphatidylcholine concentrate 700 mg twice per day
Study NCT01905605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
Study NCT02618460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non contrast-enhanced magnetic resonance imaging
Study NCT00370851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Intravitreal injection of 125 mg Avastin
Study NCT00370851 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Avastin (Bevacizumab)
Description: Intravitreal injection of 125 mg Avastin
Study NCT04175158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB222
Description: Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
Study NCT04175158 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
Study NCT04203823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cloud-based Digital Twin and Meal Prediction algorithms
Description: Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
Study NCT05063630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical treatment plus intracranial stenting
Description: This group will be both given medical treatment (aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter) and performed with intracranial stenting.
Study NCT00647218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic surgical procedure
Description: Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
Study NCT05063630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment alone
Description: This group will be given medical treatment including aspirin 100 mg and clopidogrel 75 mg per day for 90 consecutive days and clopidogrel 75 mg per day thereafter.
Study NCT00893776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task Training
Description: Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
Study NCT00893776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Training
Description: Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of point-of-care user fees
Description: User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
Study NCT00647218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent Paclitaxel
Description: Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
Study NCT00647218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Therapy
Description: After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
Study NCT00920907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
Study NCT02060448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion awareness training
Description: Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
Study NCT02060448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
Study NCT04652492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab in combination with cTACE
Description: On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
Study NCT02574312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE TKA with ATTUNE RUI
Description: ATTUNE TKA with ATTUNE RUI
Study NCT02574312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE TKA with ATTUNE SUI
Description: ATTUNE TKA with ATTUNE SUI
Study NCT01276015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
Study NCT01852357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
Study NCT01852357 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Neurofeedback
Description: Feedback generated by data not associated with the current participant.
Study NCT04308369 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood collection arm
Description: Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
Study NCT00558376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
Study NCT00558376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium phosphate
Description: Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
Study NCT03906227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENUMERATION OF CD5+ B Cells
Description: A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
Study NCT03906227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENUMERATION OF CD5+ B Cells
Description: A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
Study NCT03751774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAMAACT
Description: Post graduate training and health education materials
Study NCT02379845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBTXR3
Description: One intratumor implantation by injection
Study NCT02379845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 5 weeks/50 Gy (5 x 2 Gy by week)
Study NCT02136394 — intervention group
Intervention type: OTHER
Intervention: Gastro-esophageal reflux
Description: This is an observational study. The exposure is the gastro-esophageal reflux.
Study NCT03158545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil Placebo
Description: olive oil
Study NCT03158545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA-rich
Description: EPA-rich omega-3 oil
Study NCT03158545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA-rich
Description: DHA-rich omega-3 oil
Study NCT00974077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
Study NCT00974077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control
Description: Patients receive MBCT with a delay of 6 months.
Study NCT00842517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Study NCT00842517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Study NCT04083742 — intervention group
Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
Study NCT00339079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
Study NCT05214677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809
Description: pelubiprofen 30mg
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Removal of point-of-care user fees
Description: User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrastructure improvements at primary health centre
Description: Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infrastructure improvements at primary health centre
Description: Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of primary health centre staff
Description: Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management
Study NCT02694055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training of primary health centre staff
Description: Health center staff will receive targeted training in~* Integrated management of childhood illness~* Diagnosis and treatment of simple and severe cases of malaria~* Helping babies breathe~* Managing post-partum haemorrhage~* Gestational dating using frontal height, last menstrual period and ultrasound~* Family planning counselling and administration of long-acting contraceptives~* Pharmacy stock management~* Health center management
Study NCT03401580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 160/10
Description: once daily
Study NCT03401580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 190/10
Description: once daily
Study NCT03401580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 160/12
Description: once daily
Study NCT03401580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viena II 190/12
Description: once daily
Study NCT03059888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Subcutaneous administration of abatacept
Study NCT04179656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg administered orally, once daily, continuously in 21 day cycles
Study NCT05214677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1809-1
Description: pelubiprofen 30mg (PELUBI tab.)
Study NCT03102528 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02379845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: 5 weeks/50 Gy (5 x 2 Gy by week)
Study NCT03901703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
Study NCT00006487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
Study NCT00006487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion.
Study NCT00006487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirapazamine
Description: During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion.
Study NCT00339079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
Study NCT00339079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Description: The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
Study NCT00339079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy
Description: The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
Study NCT00881569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017 administered orally, twice daily continuously for 6 weeks
Study NCT00867763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro maturation and in vitro fertilization
Description: No gonadotropin, eggs harvested early
Study NCT00867763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low doses of gonadotropin stimulation.
Description: Gonadotropin followed by conventional IVF
Study NCT00006487 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
Study NCT02469038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath catheter
Description: Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
Study NCT02469038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
Study NCT02050971 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood Infusion
Description: Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
Study NCT02050971 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Intravenous Infusion of Peripheral Blood or its Components
Description: Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
Study NCT01555957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous lipid
Description: intravenous given daily for 6 weeks
Study NCT01555957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lipid
Description: intravenous given daily for 6 weeks
Study NCT02809261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural injection with 5% dextrose
Description: Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
Study NCT00339079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
Study NCT00541359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00541359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00541359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies